Literature DB >> 20159409

Cardiogenic shock associated with reversible dilated cardiomyopathy during therapy with regular doses of venlafaxine.

Jean-Christophe Charniot1, Noelle Vignat, Jean-Jacques Monsuez, Rachid Kidouche, Boryana Avramova, Jean-Yves Artigou, Jean-Paul Albertini.   

Abstract

We report a cardiac complication in a patient treated with regular doses of venlafaxine. A 49-year-old man with prior normal cardiac function and stable chronic hepatitis C was treated for a major depressive disorder with usual doses of venlafaxine during an 8-month period until the occurrence of a cardiogenic shock in a context of dilated cardiomyopathy. Three months after withdrawal of the drug, the left ventricular ejection fraction returned to normal values. Cardiomyopathy is a rare complication with high doses of venlafaxine that was not previously reported in patients free of prior cardiac disease and cardiomyopathy and treated with usual doses (initially 150 mg daily; after 3 months, 75 mg daily). An objective assessment revealed that venlafaxine was probably implied in the subsequent development of cardiomyopathy when considering the Naranjo Probability Scale. Physicians who usually prescribe venlafaxine have to be briefed on such potential cardiac adverse effects even with usual doses. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20159409     DOI: 10.1016/j.ajem.2009.05.010

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  5 in total

1.  Comparison of Effect of Lavandula officinalis and Venlafaxine in Treating Depression: A Double Blind Clinical Trial.

Authors:  Masoud Nikfarjam; Reza Rakhshan; Hourivash Ghaderi
Journal:  J Clin Diagn Res       Date:  2017-07-01

2.  Simultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine.

Authors:  Pedro Gonçalo Ferreira; Susana Costa; Nuno Dias; António Jorge Ferreira; Fátima Franco
Journal:  J Bras Pneumol       Date:  2014 May-Jun       Impact factor: 2.624

3.  Selective Serotonin-norepinephrine Reuptake Inhibitors-induced Takotsubo Cardiomyopathy.

Authors:  Rahul Vasudev; Upamanyu Rampal; Hiten Patel; Kunal Patel; Mahesh Bikkina; Fayez Shamoon
Journal:  N Am J Med Sci       Date:  2016-07

4.  Desvenlafaxine Overdose-induced Toxic Cardiomyopathy and Acute Left Ventricular Failure: A Case Report.

Authors:  Sandeep Kumar Goyal; Chanchal Gera; Mamta Singla; Nitin Kumar
Journal:  Indian J Psychol Med       Date:  2018 Jan-Feb

5.  Takotsubo Cardiomyopathy following a L2-L5 Laminectomy and Fusion In Situ with Bone Morphogenic Protein.

Authors:  John Weaver; Jason Eubanks
Journal:  Case Rep Orthop       Date:  2013-03-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.